| 191 |
Higher proportion of non-classical and intermediate monocytes in newly diagnosed multiple myeloma patients in Egypt: a possible prognostic marker
|
Department of Clinical Pathology |
2021 |
| 192 |
Higher proportion of non-classical and intermediate monocytes in newly diagnosed multiple myeloma patients in Egypt: a possible prognostic marker
|
Department of Medical Oncology |
2021 |
| 193 |
Higher proportion of non-classical and intermediate monocytes in newly diagnosed multiple myeloma patients in Egypt: a possible prognostic marker
|
Department of Medical Oncology |
2021 |
| 194 |
Higher proportion of non-classical and intermediate monocytes in newly diagnosed multiple myeloma patients in Egypt: a possible prognostic marker
|
Department of Clinical Pathology |
2021 |
| 195 |
HLA-B* 15 predicts survival in Egyptian patients with COVID-19 |
Department of Clinical Pathology |
2021 |
| 196 |
Increase in polymorphonuclear myeloid‑derived suppressor cells and regulatory T‑cells in children with B‑cell acute lymphoblastic leukemia |
Department of Pediatric Oncology |
2021 |
| 197 |
Interleukin-10: A Potential Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma |
Department of Clinical Pathology |
2021 |
| 198 |
Interleukin-10: A Potential Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma |
Department of Clinical Pathology |
2021 |
| 199 |
Interleukin-10: A Potential Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma |
Department of Clinical Pathology |
2021 |
| 200 |
Interleukin-10: A Potential Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma |
Department of Medical Oncology |
2021 |
